Financials data is unavailable for this security.
View more
Year on year Jiangsu Hengrui Pharmaceuticals Co Ltd grew revenues 7.26% from 21.28bn to 22.82bn while net income improved 10.14% from 3.91bn to 4.30bn.
| Gross margin | 84.74% |
|---|---|
| Net profit margin | 21.45% |
| Operating margin | 25.05% |
| Return on assets | 12.02% |
|---|---|
| Return on equity | 13.32% |
| Return on investment | 13.22% |
More ▼
Cash flow in CNYView more
In 2023, Jiangsu Hengrui Pharmaceuticals Co Ltd increased its cash reserves by 39.44%, or 5.73bn. The company earned 7.64bn from its operations for a Cash Flow Margin of 33.50%. In addition the company generated 1.22bn cash from investing, though they paid out 3.14bn more in financing than they received.
| Cash flow per share | -- |
|---|---|
| Price/Cash flow per share | -- |
| Book value per share | 6.68 |
|---|---|
| Tangible book value per share | 6.03 |
More ▼
Balance sheet in CNYView more
| Current ratio | 7.23 |
|---|---|
| Quick ratio | 6.76 |
| Total debt/total equity | 0.0081 |
|---|---|
| Total debt/total capital | 0.0079 |
More ▼
Growth rates in CNY
Year on year, both dividends per share and earnings per share excluding extraordinary items growth increased 25.00% and 11.48%, respectively. The positive trend in dividend payments is noteworthy since very few companies in the Major Drugs industry pay a dividend. Additionally when measured on a five year annualized basis, both dividend per share and earnings per share growth ranked in-line with the industry average relative to its peers.
| Div yield(5 year avg) | 0.32% |
|---|---|
| Div growth rate (5 year) | 9.45% |
| Payout ratio (TTM) | 23.49% |
| EPS growth(5 years) | 1.14 |
|---|---|
| EPS (TTM) vs TTM 1 year ago | 33.06 |
More ▼
